Literature DB >> 3911880

Randomized comparative study of amoxicillin-clavulanic acid and co-trimoxazole in the treatment of acute urinary tract infections in adults.

G N Karachalios.   

Abstract

The efficacy and safety of amoxicillin-clavulanic acid were compared with those of co-trimoxazole in the treatment of acute urinary tract infections. A total of 104 patients (mean age, 52 years) with clinical and laboratory evidence of acute urinary tract infection were enrolled in the study. Characteristics and infecting organisms were equivalent in both groups of patients. Escherichia coli was the predominant bacteria pathogen in both groups. Both drugs resulted in clinical improvement in 100% of the patients; bacteriological cure after the termination of therapy was 95% with amoxicillin-clavulanic acid and 83% with co-trimoxazole (P less than 0.001). Side effects were not severe enough to necessitate discontinuation of the antimicrobial agents. Amoxicillin-clavulanic acid is effective and safe therapy for acute urinary tract infections caused by susceptible bacteria.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3911880      PMCID: PMC176360          DOI: 10.1128/AAC.28.5.693

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

2.  Effect of clavulanic acid on the minimum inhibitory concentration of benzylpenicillin, ampicillin, carbenicillin, or cephalothin against clinical isolates resistant to beta-lactam antibiotics.

Authors:  L Dumon; P Adriaens; J Anné; H Eyssen
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

3.  Clinical experience with adverse reactions to trimethoprim-sulfamethoxazole.

Authors:  J M Frisch
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

4.  Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study.

Authors:  A P Ball; A M Geddes; P G Davey; I D Farrell; G R Brookes
Journal:  Lancet       Date:  1980-03-22       Impact factor: 79.321

Review 5.  Trimethoprim-sulfamethoxazole.

Authors:  L G Smith; J Sensakovic
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

6.  The inhibition of beta-lactamases from gram-negative bacteria by clavulanic acid.

Authors:  C Reading; T Farmer
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

7.  Clavulanic acid, a novel inhibitor of beta-lactamases.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-11       Impact factor: 5.191

  7 in total
  2 in total

1.  Oral antibiotic therapy for acute pyelonephritis: a methodologic review of the literature.

Authors:  A G Pinson; J T Philbrick; G H Lindbeck; J B Schorling
Journal:  J Gen Intern Med       Date:  1992 Sep-Oct       Impact factor: 5.128

Review 2.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.